EP0807633A3
Novel 2,3-disubstituted-(5,6)- heteroarylfused-pyrimidine-4-ones
Abstract
This record has no abstract on file.
Term
Term ended
Projected expiry passed 1 May 2017, 9.4 years ago.
- Priority
- Filed
- Published
- Projected expiry
- Today
Every citation, both waysCites: the store holds 1 of 2
| Document | Relation | Office | Category | Cited during | Relevant claims |
|---|---|---|---|---|---|
| WO9213535A1 | Cites | World Intellectual Property Organization (WIPO) | A | Search report | 1,29-36 |
16 members in 10 offices
Priority claims3
| Document | Office | Kind | Date |
|---|---|---|---|
| 1773796 | United States of America | P | |
| 1773796 | United States of America | P | |
| US19960017737P | – | – | – |
Members16
| Document | Office | Kind | |
|---|---|---|---|
| CA2205274A1 | Canada | A1 | |
| EP0807633A2 | European Patent Office (EPO) | A2 | |
| JPH1045757A | Japan | A | |
| EP0807633A3This record | European Patent Office (EPO) | A3 | |
| MX9703610A | Mexico | A | |
| US5962457A | United States of America | A | |
| JP3270360B2 | Japan | B2 | |
| EP0807633B1 | European Patent Office (EPO) | B1 | |
| AT227293T | Austria | T | |
| ATE227293T1 | Austria | T1 | |
| DK0807633T3 | Denmark | T3 | |
| DE69716810D1 | Germany | D1 | |
| CA2205274C | Canada | C | |
| DE69716810T2 | Germany | T2 | |
| PT807633E | Portugal | E | |
| ES2184960T3 | Spain | T3 |
71 legal events, as 9 offices reported them to INPADOC
Over the term
Point at a mark for the eventEvents
| Event | Code | Office | |
|---|---|---|---|
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Announcement of lapse in spainLapsedFD2A | FD2A | ES | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Notification of lapseLapsedST | ST | FR | |
| Patent lapsedLapsedMM4A | MM4A | IE | |
| Gb: european patent ceased through non-payment of renewal feeCeasedGBPC | GBPC | EP | |
| Be: lapsedLapsedBERE | BERE | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Ep patent lapsedLapsedEBP | EBP | DK | |
| Nl: lapsed or anulled due to non-payment of the annual feeLapsedNLV4 | NLV4 | EP | |
| Se: european patent has lapsedLapsedEUG | EUG | EP | |
| Patent ceasedCeasedPL | PL | CH | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Be: lapsedLapsedBERE | BERE | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| No opposition filedOpposition26N | 26N | EP | |
| No opposition filed within time limitOppositionPLBE | PLBE | EP | |
| Information on the status of an ep patent application or granted ep patentGrantedSTAA | STAA | EP | |
| Definitive protectionFG2A | FG2A | ES | |
| Fr: translation filedET | ET | EP | |
| Translation is availableSC4A | SC4A | PT | |
| Ep patent validated in greeceEP | EP | GR | |
| New agentNV | NV | CH | |
| Corresponds to:REF | REF | EP | |
| European patents granted designating irelandGrantedFG4D | FG4D | IE | |
| Ep patent with danish claimsT3 | T3 | DK | |
| European patent takes effect as a national patent in ch/liEP | EP | CH | |
| Designated contracting statesAK | AK | EP | |
| European patent grantedGrantedFG4D | FG4D | GB | |
| Corresponds to:REF | REF | EP | |
| (expected) grantGRAA | GRAA | EP | |
| Despatch of communication of intention to grant a patentGRAH | GRAH | EP | |
| Despatch of communication of intention to grantGRAG | GRAG | EP | |
| Despatch of communication of intention to grant a patentGRAH | GRAH | EP | |
| Despatch of communication of intention to grantGRAG | GRAG | EP | |
| Despatch of communication of intention to grantGRAG | GRAG | EP | |
| First examination report despatched17Q | 17Q | EP | |
| Designated contracting statesAK | AK | EP | |
| Search report despatchedPUAL | PUAL | EP | |
| Request for examination filed17P | 17P | EP | |
| Designated contracting statesAK | AK | EP | |
| Public reference made under article 153(3) epc to a published international application that has entered the european phasePUAI | PUAI | EP |
Numbers
- Publication, DOCDB
- 0807633
- Publication, EPODOC
- EP0807633
- Application
- 97303000
- Application, DOCDB
- 97303000
- Application, EPODOC
- EP19970303000
Titles3
- German
- 2,3-Disubstituierte-(5,6)-heteroarylkondensierte-pyrimidin-4-one
- English
- Novel 2,3-disubstituted-(5,6)- heteroarylfused-pyrimidine-4-ones
- French
- (5,6)-Pyrimidin-4-ones condensées à hétéroaryle, substituées en 2,3
Classification
- CPC, 25
- C07D471/04
- C07D475/02
- C07D487/04
- C07D495/04
- A61P1/08
- A61P13/00
- A61P13/02
- A61P15/00
- A61P25/00
- A61P25/02
- A61P25/04
- A61P25/08
- A61P25/14
- A61P25/16
- A61P25/18
- A61P25/20
- A61P25/22
- A61P25/28
- A61P25/30
- A61P25/32
- A61P25/34
- A61P27/02
- A61P43/00
- A61P9/00
- A61P9/10
- IPC, 28
- A61K31 505
- A61K31 519
- A61P1 08
- A61P9 00
- A61P9 10
- A61P13 00
- A61P13 02
- A61P15 00
- A61P25 00
- A61P25 02
- A61P25 04
- A61P25 08
- A61P25 14
- A61P25 16
- A61P25 18
- A61P25 20
- A61P25 22
- A61P25 28
- A61P25 30
- A61P25 32
- A61P25 34
- A61P27 02
- A61P43 00
- C07D471 04
- C07D475 02
- C07D487 04
- C07D491 048
- C07D495 04
Designated states17
- Contracting states, 17
- Austria
- Belgium
- Switzerland
- Germany
- Denmark
- Spain
- Finland
- France
- United Kingdom
- Greece
- Ireland
- Italy
- Liechtenstein
- Luxembourg
- Netherlands (Kingdom of the)
- Portugal
- Sweden